Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) kicked off on Friday, down -5.28% from the previous trading day, before settling in for the closing price of $25.01. Over the past 52 weeks, CNTA has traded in a range of $9.60-$30.58.
Healthcare Sector giant saw their annual sales slid by -210.04% over the last five years. While this was happening, its average annual earnings per share was recorded 32.29%. With a float of $88.33 million, this company’s outstanding shares have now reached $134.42 million.
Centessa Pharmaceuticals plc ADR (CNTA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 34.29%, while institutional ownership is 59.86%. The most recent insider transaction that took place on Jan 02 ’26, was worth 60,750,000. Before that another transaction happened on Dec 09 ’25, when Company’s President, Orexin Program sold 10,000 for $28.83, making the entire transaction worth $288,289. This insider now owns 178,801 shares in total.
Centessa Pharmaceuticals plc ADR (CNTA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.58 earnings per share (EPS), lower than consensus estimate (set at -0.35) by -0.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.96% during the next five years compared to -210.04% drop over the previous five years of trading.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Take a look at Centessa Pharmaceuticals plc ADR’s (CNTA) current performance indicators. Last quarter, stock had a quick ratio of 10.57. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 211.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.82, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
As of the previous 9 days, the stock’s Stochastic %D was 33.08%.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 55.75%, which indicates a significant increase from 4.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.09 in the past 14 days, which was lower than the 1.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.07, while its 200-day Moving Average is $18.54. Now, the first resistance to watch is $24.77. This is followed by the second major resistance level at $25.85. The third major resistance level sits at $26.49. If the price goes on to break the first support level at $23.05, it is likely to go to the next support level at $22.41. Now, if the price goes above the second support level, the third support stands at $21.33.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
The company with the Market Capitalisation of 3.18 billion has total of 134,421K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -235,760 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -50,340 K.
